Skip to content

Study · Randomized controlled trial · n = 977 · 2005

4 results

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D

International journal of radiation oncology, biology, physics1 Apr 2005Cited by 641 (Europe PMC)

PMID15817329 (opens in a new tab)DOI10.1016/j.ijrobp.2004.08.047 (opens in a new tab)PepBankPUB-15817329
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In unfavorable-prognosis prostate cancer, adjuvant goserelin improved survival to 49% versus 39% with control (p = 0.002).

    In plain wordsIn unfavorable-prognosis prostate cancer, adjuvant goserelin improved survival compared with goserelin at relapse.

    Peptide
    Goserelin
    Outcome
    IncreaseAbsolute survival at 10 years
    Study

    n = 977

    Comparator
    Radiotherapy with goserelin at relapse
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated · Indefinitely or until progressionAs given in this study (human).

    Measurements

    Absolute survival at 10 years
    49%
    adjuvant goserelin arm
    Absolute survival at 10 years
    39%
    control arm

    Source sentences

    Summary
    At 10 years, the absolute survival rate was significantly greater for the adjuvant arm than for the control arm: 49% vs. 39%, respectively (p = 0.002).
    3 context sentences
    Summary · context
    Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement.
    Summary · context
    The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II).
    Summary · context
    In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In unfavorable-prognosis prostate cancer, adjuvant goserelin reduced local failure to 23% versus 38% with control (p <0.0001).

    In plain wordsIn unfavorable-prognosis prostate cancer, adjuvant goserelin reduced local failure compared with goserelin at relapse.

    Peptide
    Goserelin
    Outcome
    DecreaseLocal failure at 10 years
    Study

    n = 977

    Comparator
    Radiotherapy with goserelin at relapse
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · Indefinitely or until progressionAs given in this study (human).

    Measurements

    Local failure rate at 10 years
    23%
    adjuvant goserelin arm
    Local failure rate at 10 years
    38%
    control arm

    Source sentences

    Summary
    The 10-year local failure rate for the adjuvant arm was 23% vs. 38% for the control arm (p <0.0001).
    3 context sentences
    Summary · context
    Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement.
    Summary · context
    The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II).
    Summary · context
    In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In unfavorable-prognosis prostate cancer, adjuvant goserelin reduced distant metastases to 24% versus 39% with control (p <0.001).

    In plain wordsIn unfavorable-prognosis prostate cancer, adjuvant goserelin reduced distant metastases compared with goserelin at relapse.

    Peptide
    Goserelin
    Outcome
    DecreaseDistant metastases at 10 years
    Study

    n = 977

    Comparator
    Radiotherapy with goserelin at relapse
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · Indefinitely or until progressionAs given in this study (human).

    Measurements

    Distant metastases incidence at 10 years
    24%
    adjuvant goserelin arm
    Distant metastases incidence at 10 years
    39%
    control arm

    Source sentences

    Summary
    The corresponding 10-year rates for the incidence of distant metastases and disease-specific mortality was 24% vs. 39% (p <0.001) and 16% vs. 22% (p = 0.0052), respectively, both in favor of the adjuvant arm.
    3 context sentences
    Summary · context
    Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement.
    Summary · context
    The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II).
    Summary · context
    In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In unfavorable-prognosis prostate cancer, adjuvant goserelin reduced disease-specific mortality to 16% versus 22% with control (p = 0.0052).

    In plain wordsIn unfavorable-prognosis prostate cancer, adjuvant goserelin reduced cancer mortality compared with goserelin at relapse.

    Peptide
    Goserelin
    Outcome
    DecreaseDisease-specific mortality at 10 years
    Study

    n = 977

    Comparator
    Radiotherapy with goserelin at relapse
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated · Indefinitely or until progressionAs given in this study (human).

    Measurements

    Disease-specific mortality at 10 years
    16%
    adjuvant goserelin arm
    Disease-specific mortality at 10 years
    22%
    control arm

    Source sentences

    Summary
    The corresponding 10-year rates for the incidence of distant metastases and disease-specific mortality was 24% vs. 39% (p <0.001) and 16% vs. 22% (p = 0.0052), respectively, both in favor of the adjuvant arm.
    3 context sentences
    Summary · context
    Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement.
    Summary · context
    The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II).
    Summary · context
    In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT04249154

Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centren = 773 Sept 2019 to est. 15 Dec 2027

Prostate Cancer

Trial pageClinicalTrials.govUpdated 25 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.